NRX Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
NRX Pharmaceuticals, Inc. (NRXP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 790.02 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2024-03-29
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-12-31 was 15.00K shares.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-09-30 was 131.54K shares.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-06-30 was 550.83K shares.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2022-03-31 was 45.37K shares.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 790.02K shares, a 6.37% increase from fiscal 2022.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 742.74K shares, a 90.35% increase from fiscal 2021.
- NRX Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 390.19K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2023-12-31 | 790.02K shares 10-K · filed 2024-03-29 | |||
| 2022-12-31 | 15.00K shares derived: 10-K 12 month − 3 quarters · filed 2023-03-31 | 146.54K shares derived: sum of 2 quarters · filed 2023-03-31 | 697.37K shares derived: sum of 3 quarters · filed 2023-03-31 | 742.74K shares 10-K · filed 2023-03-31 |
| 2022-09-30 | 131.54K shares 10-Q · filed 2022-11-14 | 682.37K shares derived: sum of 2 quarters · filed 2022-11-14 | 727.74K shares derived: sum of 3 quarters · filed 2022-11-14 | |
| 2022-06-30 | 550.83K shares 10-Q · filed 2022-11-14 | 596.20K shares derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2022-03-31 | 45.37K shares 10-Q · filed 2022-11-14 | |||
| 2021-12-31 | 390.19K shares 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |